
Evolution of Cefiderocol Non-Susceptibility inPseudomonas aeruginosain a Patient Without Previous Exposure to the Antibiotic
Author(s) -
Ana Paula Streling,
Mohanad M. Al Obaidi,
William Lainhart,
Tirdad T. Zangeneh,
Ayesha Khan,
An Q Dinh,
Blake Hanson,
César A. Arias,
William R. Miller
Publication year - 2021
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa1909
Subject(s) - pseudomonas aeruginosa , cephalosporin , siderophore , antibiotics , genome , biology , medicine , microbiology and biotechnology , pseudomonas , genetics , bacteria , gene
We report the emergence of non-susceptibility to cefiderocol from a subpopulation of Pseudomonas aeruginosa recovered from a patient without history of cefiderocol exposure. Whole genome sequencing identified mutations in major iron transport pathways previously associated with cefiderocol uptake. Susceptibility testing should be performed before therapy with siderophore cephalosporins.